FindMyKOL
Clinical trialNCT03847636CompletedInterventional

CryoBalloon Ablation for Treatment of Duodenal Adenomas

NCT03847636 is an interventional trial sponsored by Johns Hopkins University. As of 21 Nov 2026, it is completed. It studies Duodenal Adenomas and Familial Adenomatous Polyposis. The registry lists an enrollment of 33 participants at 4 sites in 1 country. The registry lists a start date of 13 May 2019 and a primary completion date of 1 Jun 2025.

SponsorJohns Hopkins University →Enrollment33Duodenal AdenomasFamilial Adenomatous Polyposis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03847636
FieldValue
Registry IDNCT03847636
StatusCompleted
Study typeInterventional trial
Lead sponsorJohns Hopkins University
Enrollment33
Registered sites4
Countries1
ConditionsDuodenal Adenomas and Familial Adenomatous Polyposis
Start13 May 2019
Primary completion1 Jun 2025
Study completion1 Jun 2026
Last update posted5 Aug 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This multicenter prospective non-randomized interventional study (clinical trial) that will assess the safety and efficacy of cryoballoon ablation treatment using the C2 Cryoballoon device (Pentax Medical Corporation) as an alternative primary treatment modality for sporadic and familial nonampullary nonpolypoid (flat) duodenal adenomas.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Maryland, United States1 site
  • Johns Hopkins Hospital

    Baltimore

New York, United States1 site
  • Northwell Health

    Manhasset

Pennsylvania, United States1 site
  • Geisinger Medical Center

    Danville

Texas, United States1 site
  • Methodist Dallas Medical Center

    Dallas

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT03847636

Each answer restates registry values shown on this page.

What is NCT03847636?

NCT03847636 is an interventional trial sponsored by Johns Hopkins University. It studies Duodenal Adenomas and Familial Adenomatous Polyposis.

Who leads NCT03847636?

The registry names Marcia I. Canto, MD (principal investigator, Johns Hopkins University) as the overall official.

Where does NCT03847636 run?

The registry lists 4 sites in 1 country. Every site with a stated country is in one country: United States.

When did NCT03847636 end?

The registry lists a primary completion date of 1 Jun 2025 and a study completion date of 1 Jun 2026. The sponsor last updated the record on 5 Aug 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.